Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients
Alexandr Y Mayorov, Anna A Mosikian, Diana N Alpenidze, Igor E Makarenko, Valeria L Orlova, Ivan S Lunev, Maria V Verbovaya, Bella R Zinnatulina, Alexander L Khokhlov, Roman V Drai, Alexandr Y Mayorov, Anna A Mosikian, Diana N Alpenidze, Igor E Makarenko, Valeria L Orlova, Ivan S Lunev, Maria V Verbovaya, Bella R Zinnatulina, Alexander L Khokhlov, Roman V Drai
Abstract
Aim: To compare safety (immunogenicity) and efficacy of a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25) in Type 2 diabetes mellitus (T2D) patients. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 210 T2D patients, randomized 1:1 to twice-daily GP-Lis25 or Ly-Lis25. The primary end point was immune response at 26th week. Noninferiority margin for HbA1c was 0.4%. Results: Immune response frequency was similar in GP-Lis25 and Ly-Lis25 groups both at week 12 (p = 0.651) and 26 (p = 0.164). The difference of HbA1c change at week 26 was (95% CI) 0.01 (-0.27-0.28)%. Fasting plasma glucose, seven-point glucose profile and insulin dose were similar between groups. Safety did not differ between groups. Conclusion: GP-Lis25 and Ly-Lis25 demonstrated similar safety and efficacy. ClincalTrials.gov identifier: NCT04023344.
Keywords: GP-Lis; Ly-Lis; biosimilar insulin; diabetes mellitus.
Source: PubMed